{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:37:21Z","timestamp":1792705041461,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11,1]]},"DOI":"10.1093\/infdis\/jis508","type":"journal-article","created":{"date-parts":[[2012,8,22]],"date-time":"2012-08-22T00:38:22Z","timestamp":1345595902000},"page":"1453-1461","source":"Crossref","is-referenced-by-count":55,"title":["A Single-Nucleotide Polymorphism in CYP2B6 Leads to >3-Fold Increases in Efavirenz Concentrations in Plasma and Hair Among HIV-Infected Women"],"prefix":"10.1093","volume":"206","author":[{"given":"Monica","family":"Gandhi","sequence":"first","affiliation":[{"name":"Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth M.","family":"Greenblatt","sequence":"additional","affiliation":[{"name":"Department of Medicine"},{"name":"Department of Clinical Pharmacy"},{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco (UCSF)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bacchetti","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco (UCSF)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengshi","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco (UCSF)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Anastos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Albert Einstein University, Bronx"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mardge","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stroger Hospital"},{"name":"Department of Medicine , Rush University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack A.","family":"DeHovitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, SUNY Downstate Medical Center, Brooklyn, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald B.","family":"Sharp","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Gange","sequence":"additional","affiliation":[{"name":"Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Georgetown University Medical Center, Washington, D. C"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Department of Physiological Nursing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Aouizerat","sequence":"additional","affiliation":[{"name":"Department of Physiological Nursing"},{"name":"Institute for Human Genetics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Women's Interagency HIV Study","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,8,20]]},"reference":[{"key":"key\n\t\t\t\t20180328180851_JIS508C1","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1002\/rcm.3750","article-title":"Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry","volume":"22","author":"Huang","year":"2008","journal-title":"Rapid Commun Mass Spectrom"},{"key":"key\n\t\t\t\t20180328180851_JIS508C2","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00216-011-5278-7","article-title":"Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry","volume":"401","author":"Huang","year":"2011","journal-title":"Anal Bioanal Chem"},{"key":"key\n\t\t\t\t20180328180851_JIS508C3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/cir131","article-title":"Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy","volume":"52","author":"Gandhi","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328180851_JIS508C4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/QAD.0b013e328325a4a9","article-title":"Protease inhibitor levels in hair strongly predict virologic response to treatment","volume":"23","author":"Gandhi","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328180851_JIS508C5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00001648-199803000-00004","article-title":"The women's interagency HIV study. WIHS collaborative study group","volume":"9","author":"Barkan","year":"1998","journal-title":"Epidemiology"},{"key":"key\n\t\t\t\t20180328180851_JIS508C6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/QAI.0b013e31819c3376","article-title":"Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women","volume":"50","author":"Gandhi","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328180851_JIS508C7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2165\/00003088-200544080-00006","article-title":"Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals","volume":"44","author":"Kappelhoff","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20180328180851_JIS508C8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2125.2006.02834.x","article-title":"Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice","volume":"63","author":"Molto","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180328180851_JIS508C9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/QAI.0b013e31813e5e20","article-title":"Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients: the role of gender","volume":"46","author":"Smith","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328180851_JIS508C10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00126334-200404150-00007","article-title":"Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study","volume":"35","author":"Manfredi","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328180851_JIS508C11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAI.0b013e3181a572cf","article-title":"Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients","volume":"51","author":"Dejesus","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328180851_JIS508C12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1468-1293.2010.00877.x","article-title":"A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study","volume":"12","author":"Reekie","year":"2011","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20180328180851_JIS508C13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328180851_JIS508C14","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1086\/497835","article-title":"Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring","volume":"41","author":"Gutierrez","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328180851_JIS508C15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS clinical trials group study","volume":"202","author":"Ribaudo","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328180851_JIS508C16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogen and Genom"},{"key":"key\n\t\t\t\t20180328180851_JIS508C17","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328180851_JIS508C18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/FPC.0b013e328328d577","article-title":"In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function","volume":"19","author":"di Iulio","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"key\n\t\t\t\t20180328180851_JIS508C19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0140-6736(02)07276-8","article-title":"Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study","volume":"359","author":"Fellay","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328180851_JIS508C20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2217\/14622416.8.6.623","article-title":"ADME pathway approach for pharmacogenetic studies of anti-HIV therapy","volume":"8","author":"Lubomirov","year":"2007","journal-title":"Pharmacogenomics"},{"key":"key\n\t\t\t\t20180328180851_JIS508C21","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/00007691-200410000-00014","article-title":"Automated, fast, and sensitive quantification of drugs in human plasma by LC\/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors","volume":"26","author":"Egge-Jacobsen","year":"2004","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t20180328180851_JIS508C22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0009-9120(02)00286-2","article-title":"Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem mass-spectrometry","volume":"35","author":"Volosov","year":"2002","journal-title":"Clin Biochem"},{"key":"key\n\t\t\t\t20180328180851_JIS508C23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00001648-199001000-00013","article-title":"A reduced dietary questionnaire: development and validation","volume":"1","author":"Block","year":"1990","journal-title":"Epidemiology"},{"key":"key\n\t\t\t\t20180328180851_JIS508C24","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1126\/science.1069424","article-title":"The structure of haplotype blocks in the human genome","volume":"296","author":"Gabriel","year":"2002","journal-title":"Science"},{"key":"key\n\t\t\t\t20180328180851_JIS508C25","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1086\/319501","article-title":"A new statistical method for haplotype reconstruction from population data","volume":"68","author":"Stephens","year":"2001","journal-title":"Am J Hum Genet"},{"key":"key\n\t\t\t\t20180328180851_JIS508C26","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/humu.20695","article-title":"A panel of ancestry informative markers for estimating individual biogeographical ancestry and admixture from four continents: utility and applications","volume":"29","author":"Halder","year":"2008","journal-title":"Hum Mutat"},{"key":"key\n\t\t\t\t20180328180851_JIS508C27","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/ng1847","article-title":"Principal components analysis corrects for stratification in genome-wide association studies","volume":"38","author":"Price","year":"2006","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20180328180851_JIS508C28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cmpb.2003.08.004","article-title":"Mixed models for longitudinal left-censored repeated measures","volume":"74","author":"Thi\u00e9baut","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"key\n\t\t\t\t20180328180851_JIS508C29","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1177\/135965350701200808","article-title":"Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification","volume":"12","author":"Keiser","year":"2007","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180328180851_JIS508C30","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJMra1010600","article-title":"Genomics and drug response","volume":"364","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328180851_JIS508C31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/clpt.2008.271","article-title":"Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals","volume":"85","author":"Arab-Alameddine","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180328180851_JIS508C32","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1086\/597125","article-title":"Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans","volume":"199","author":"Haas","year":"2009","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328180851_JIS508C33","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1128\/AAC.01537-08","article-title":"Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients","volume":"53","author":"Cabrera","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328180851_JIS508C34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/499364","article-title":"Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an adults AIDS clinical trials group study","volume":"42","author":"Ribaudo","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328180851_JIS508C35","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328180851_JIS508C36","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/497610","article-title":"Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and\/or nelfinavir: an adult AIDS clinical trails group study","volume":"192","author":"Haas","year":"2005","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328180851_JIS508C37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.2005.02536.x","article-title":"Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism","volume":"61","author":"Burger","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180328180851_JIS508C38","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1128\/AAC.00194-11","article-title":"Population pharmacokinetic\/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients","volume":"55","author":"Sanchez","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328180851_JIS508C39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-011-1118-0","article-title":"CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans","volume":"68","author":"Maimbo","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180328180851_JIS508C40","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/QAD.0b013e32830e011f","article-title":"The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir\/ritonavir in HIV-infected persons requiring hemodialysis","volume":"22","author":"Gupta","year":"2008","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328180851_JIS508C41","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1345\/aph.1P141","article-title":"Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms","volume":"44","author":"Lindfelt","year":"2010","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20180328180851_JIS508C42","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1086\/429327","article-title":"Influence of 516G>T polymorphisms at the gene encoding the CYP450\u20132B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects","volume":"40","author":"Rodriguez-Novoa","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328180851_JIS508C43","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2004.05.116","article-title":"Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens","volume":"319","author":"Tsuchiya","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"key\n\t\t\t\t20180328180851_JIS508C44","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-011-1118-0","article-title":"CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans","volume":"68","author":"Maimbo","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180328180851_JIS508C45","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/jac\/dkr272","article-title":"Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens","volume":"66","author":"Wyen","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328180851_JIS508C46","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/infdis\/jiq043","article-title":"Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study","volume":"203","author":"Lubomirov","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328180851_JIS508C47","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00228-007-0440-z","article-title":"Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?","volume":"64","author":"Rotger","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180328180851_JIS508C48","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1086\/501458","article-title":"Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring","volume":"42","author":"Nettles","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328180851_JIS508C49","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1310\/hct0904-238","article-title":"White coat compliance limits the reliability of therapeutic drug monitoring in HIV-1-infected patients","volume":"9","author":"Podsadecki","year":"2008","journal-title":"HIV Clin Trials"},{"key":"key\n\t\t\t\t20180328180851_JIS508C50","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1742-1241.2001.tb11062.x","article-title":"Hair as a biological specimen for therapeutic drug monitoring","volume":"55","author":"Beumer","year":"2001","journal-title":"Int J Clin Pract"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/206\/9\/1453\/13803840\/jis508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T11:15:55Z","timestamp":1687691755000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/206\/9\/1453\/825421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,20]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2012,8,20]]},"published-print":{"date-parts":[[2012,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jis508","relation":{},"ISSN":["1537-6613","0022-1899"],"issn-type":[{"value":"1537-6613","type":"electronic"},{"value":"0022-1899","type":"print"}],"subject":[],"published-other":{"date-parts":[[2012,11,1]]},"published":{"date-parts":[[2012,8,20]]}}}